Human leukocyte antigen-DR/DQ eplet mismatch analysis for primary alloimmune risk stratification of non-sensitized kidney transplant recipients
Korean Journal of Transplantation · 2020
DOI: 10.4285/atw2020.op-1071 ↗At a glance
Journal article in Korean Journal of Transplantation, 2020. Written by Hyeyoung Lee and 5 co-authors.
Abstract (original language)
Background
Human leukocyte antigen (HLA) analysis has been suggested as a predictive tool for alloimmune risk stratification in kidney transplantation (KT). We investigated whether the whole or single molecule HLA class II eplet mismatch was related to the de-novo donor-specific-antibody (dnDSA) development or antibody-mediated rejection (AMR).
Methods
Total 300 kidney transplants performed at Seoul St. Mary’s Hospital between 2016 December and 2020 January with out preformed DSA have been analyzed. HLA class II eplet mismatches were determined by high resolution HLA DRB1/DQB1 typing results and HLA Matchmaker program.
Results
During the 22.6 months (median) follow-up period, 24 recipients developed HLA class II dnDSA and 20 patients diag nosed as AMR. Using receiver operating characteristic analysis, we identified eplet mismatch thresholds associated with dnDSA development and stratified recipients into low-, intermediate-, and high-risk categories. In whole eplet mismatch analysis, risk categories were significantly correlated with dnDSA development (log-rank P-value 8 predicted dnDSA development with 75% sensitivity and 63.4% specificity. Risk categories by single molecular eplet mis match also had significant correlation with dnDSA development (log-rank P-value= 0.001) with significant difference between low (HLA-DR ≤7 and HLA-DQ ≤4) (n=78) and intermediate (HLA-DR ≥8 and HLA-DQ ≤6 or HLA-DR 0-7 and HLA-DQ 5-6) (n=95) group (P=0.026). High-risk group (HLA-DR 0-20 and HLA DQ 7-17) predicted dnDSA development with 75% sensitivity and 60.5% specificity. Both eplet mismatch risk categories were significantly associated with AMR, but no differences were found among risk groups.
Conclusions
HLA class II eplet mismatches showed the possibility of being used as a clinically relevant parameter in alloim mune risk assessments of KT.
Cite
APA
Lee, H., Min, J. W., Kang, H., Yang, C. W., Chung, B. H., & Oh, E. (2020). Human leukocyte antigen-DR/DQ eplet mismatch analysis for primary alloimmune risk stratification of non-sensitized kidney transplant recipients. Korean Journal of Transplantation. https://doi.org/10.4285/atw2020.op-1071
Vancouver
Lee H, Min JW, Kang H, Yang CW, Chung BH, Oh E. Human leukocyte antigen-DR/DQ eplet mismatch analysis for primary alloimmune risk stratification of non-sensitized kidney transplant recipients. Korean Journal of Transplantation. 2020. doi:10.4285/atw2020.op-1071
BibTeX
@article{Lee2020,
author = {Lee, Hyeyoung and Min, Ji Won and Kang, Hyunhye and Yang, Chul Woo and Chung, Byung Ha and Oh, Eun-Jee},
title = {Human leukocyte antigen-DR/DQ eplet mismatch analysis for primary alloimmune risk stratification of non-sensitized kidney transplant recipients},
journal = {Korean Journal of Transplantation},
year = {2020},
doi = {10.4285/atw2020.op-1071}
}
EUVIMED